Skip to content

Study · Randomized controlled trial · n = 60 · 2012

11 results

Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK

The Journal of clinical endocrinology and metabolism26 Sept 2012Cited by 40 (Europe PMC)

PMID23015655 (opens in a new tab)PMCIDPMC3513535 (opens in a new tab)DOI10.1210/jc.2012-2794 (opens in a new tab)PepBankPUB-23015655
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In abdominally obese adults with reduced GH secretion, tesamorelin reduced visceral adipose tissue versus placebo over 12 months.

    In plain wordsIn abdominally obese adults with low growth hormone, tesamorelin reduced belly (visceral) fat more than placebo over 12 months.

    Peptide
    Tesamorelin
    Outcome
    DecreaseVisceral adipose tissue
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 mg · 12 monthsAs given in this study (human).

    Measurements

    Treatment effect on VAT
    −35 cm(2)
    tesamorelin vs placebo

    Source sentences

    Summary
    VAT [-16 ± 9 vs.19 ± 9 cm(2), tesamorelin vs. placebo; treatment effect (95% confidence interval): -35 (-58, -12) cm(2); P = 0.003]
    2 context sentences
    Summary · context
    A randomized, double-blind, placebo-controlled study was performed involving 60 abdominally obese subjects with reduced GH secretion.
    Summary · context
    Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for 12 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In abdominally obese adults with reduced GH secretion, tesamorelin reduced carotid intima-media thickness versus placebo over 12 months.

    In plain wordsIn abdominally obese adults with low growth hormone, tesamorelin reduced carotid artery wall thickness more than placebo over 12 months.

    Peptide
    Tesamorelin
    Outcome
    DecreaseCarotid intima-media thickness
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    2 mg · 12 monthsAs given in this study (human).

    Measurements

    Treatment effect on cIMT
    −0.04 mm
    tesamorelin vs placebo

    Source sentences

    Summary
    cIMT (-0.03 ± 0.01 vs. 0.01 ± 0.01 mm; -0.04 (-0.07, -0.01) mm; P = 0.02)
    2 context sentences
    Summary · context
    A randomized, double-blind, placebo-controlled study was performed involving 60 abdominally obese subjects with reduced GH secretion.
    Summary · context
    Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for 12 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In abdominally obese adults with reduced GH secretion, tesamorelin lowered log C-reactive protein versus placebo over 12 months.

    In plain wordsIn abdominally obese adults with low growth hormone, tesamorelin lowered the inflammation marker C-reactive protein more than placebo over 12 months.

    Peptide
    Tesamorelin
    Outcome
    DecreaseLog C-reactive protein
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    2 mg · 12 monthsAs given in this study (human).

    Measurements

    Treatment effect on log CRP
    −0.15 mg/liter
    tesamorelin vs placebo

    Source sentences

    Summary
    log C-reactive protein (-0.17 ± 0.04 vs. -0.03 ± 0.05 mg/liter; -0.15 (-0.30, -0.01) mg/liter, P = 0.04)
    2 context sentences
    Summary · context
    A randomized, double-blind, placebo-controlled study was performed involving 60 abdominally obese subjects with reduced GH secretion.
    Summary · context
    Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for 12 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In abdominally obese adults with reduced GH secretion, tesamorelin lowered triglycerides versus placebo over 12 months.

    In plain wordsIn abdominally obese adults with low growth hormone, tesamorelin lowered triglycerides more than placebo over 12 months.

    Peptide
    Tesamorelin
    Outcome
    DecreaseTriglycerides
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    2 mg · 12 monthsAs given in this study (human).

    Measurements

    Treatment effect on triglycerides
    −37 mg/dl
    tesamorelin vs placebo

    Source sentences

    Summary
    and triglycerides (-26 ± 16 vs. 12 ± 8 mg/dl; -37 (-67, -7) mg/dl; P = 0.02) improved significantly in the tesamorelin group vs. placebo.
    2 context sentences
    Summary · context
    A randomized, double-blind, placebo-controlled study was performed involving 60 abdominally obese subjects with reduced GH secretion.
    Summary · context
    Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for 12 months.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In abdominally obese adults with reduced GH secretion, tesamorelin had no significant effect on abdominal subcutaneous adipose tissue versus placebo.

    In plain wordsIn abdominally obese adults with low growth hormone, tesamorelin did not significantly change fat under the skin of the belly compared with placebo.

    Peptide
    Tesamorelin
    Outcome
    No significant changeAbdominal subcutaneous adipose tissue
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 mg · 12 monthsAs given in this study (human).

    Measurements

    Treatment effect on SC adipose tissue
    −10 cm(2)
    tesamorelin vs placebo

    Source sentences

    Summary
    No significant effects on abdominal sc adipose tissue (-6 ± 6 vs. 3 ± 11 cm(2); -10 (-32, +13) cm(2); P = 0.40) were seen.
    2 context sentences
    Summary · context
    A randomized, double-blind, placebo-controlled study was performed involving 60 abdominally obese subjects with reduced GH secretion.
    Summary · context
    Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for 12 months.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In abdominally obese adults with reduced GH secretion, tesamorelin increased IGF-I versus placebo over 12 months.

    In plain wordsIn abdominally obese adults with low growth hormone, tesamorelin raised IGF-I more than placebo over 12 months.

    Peptide
    Tesamorelin
    Outcome
    IncreaseIGF-I
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 mg · 12 monthsAs given in this study (human).

    Measurements

    Treatment effect on IGF-I
    92 μg/liter
    tesamorelin vs placebo

    Source sentences

    Summary
    IGF-I increased (86 ± 21 vs. -6 ± 8 μg/liter; 92 (+52, +132) μg/liter; P < 0.0001).
    2 context sentences
    Summary · context
    A randomized, double-blind, placebo-controlled study was performed involving 60 abdominally obese subjects with reduced GH secretion.
    Summary · context
    Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for 12 months.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In abdominally obese adults with reduced GH secretion, tesamorelin did not change fasting glucose versus placebo.

    In plain wordsIn abdominally obese adults with low growth hormone, tesamorelin did not change fasting blood sugar compared with placebo.

    Peptide
    Tesamorelin
    Outcome
    No significant changeFasting glucose
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    No changes in fasting, 2-h glucose, or glycated hemoglobin were seen.
    2 context sentences
    Summary · context
    A randomized, double-blind, placebo-controlled study was performed involving 60 abdominally obese subjects with reduced GH secretion.
    Summary · context
    Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for 12 months.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In abdominally obese adults with reduced GH secretion, tesamorelin did not change 2-hour glucose versus placebo.

    In plain wordsIn abdominally obese adults with low growth hormone, tesamorelin did not change 2-hour blood sugar compared with placebo.

    Peptide
    Tesamorelin
    Outcome
    No significant change2-hour glucose
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    No changes in fasting, 2-h glucose, or glycated hemoglobin were seen.
    2 context sentences
    Summary · context
    A randomized, double-blind, placebo-controlled study was performed involving 60 abdominally obese subjects with reduced GH secretion.
    Summary · context
    Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for 12 months.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In abdominally obese adults with reduced GH secretion, tesamorelin did not change glycated hemoglobin versus placebo.

    In plain wordsIn abdominally obese adults with low growth hormone, tesamorelin did not change HbA1c compared with placebo.

    Peptide
    Tesamorelin
    Outcome
    No significant changeGlycated hemoglobin
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    No changes in fasting, 2-h glucose, or glycated hemoglobin were seen.
    2 context sentences
    Summary · context
    A randomized, double-blind, placebo-controlled study was performed involving 60 abdominally obese subjects with reduced GH secretion.
    Summary · context
    Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for 12 months.
  10. 10HumanRandomized controlled trialSafety outcome

    In abdominally obese adults with reduced GH secretion, there were no serious adverse events.

    In plain wordsIn abdominally obese adults with low growth hormone, there were no serious side effects.

    Peptide
    Tesamorelin
    Outcome
    No significant changeSerious adverse events
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    2 mg · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no serious adverse events
    2 context sentences
    Summary · context
    A randomized, double-blind, placebo-controlled study was performed involving 60 abdominally obese subjects with reduced GH secretion.
    Summary · context
    Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for 12 months.
  11. 11HumanRandomized controlled trialSafety outcome

    In abdominally obese adults with reduced GH secretion, adverse events did not differ between tesamorelin and placebo.

    In plain wordsIn abdominally obese adults with low growth hormone, side effects were similar with tesamorelin and with placebo.

    Peptide
    Tesamorelin
    Outcome
    No significant changeAdverse events overall
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    2 mg · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no serious adverse events or differences in adverse events between the groups.
    2 context sentences
    Summary · context
    A randomized, double-blind, placebo-controlled study was performed involving 60 abdominally obese subjects with reduced GH secretion.
    Summary · context
    Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00675506

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

Massachusetts General Hospitaln = 60Jul 2008 to Jan 2012

Abdominal Obesity · Growth Hormone Deficiency

Trial pageClinicalTrials.govUpdated 13 Dec 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.